BiopharmaVantage is pleased to announce that it has acted as advisor for a public traded investment company for its investment into immunotherapy business. The investee company is developing state-of-the art immunotherapeutic interventions for cancer treatment using its novel and proprietary platform.

BiopharmaVantage’s lead advisor, Dr Shreesh Saurya, managing the engagement commented: "Immunotherapy is an attractive opportunity. The market is currently relatively oligopolistic, and there will be several new entrants in the future. We have conducted an objective assessment of the business leveraging our deep understanding of the sector. We believe that the platform offered by the investee company is differentiated and offers a significant competitive advantage. The investment will allow the company to embark on growth while simultaneously create value for its investors and other stakeholders.

About BiopharmaVantage

BiopharmaVantage is a consultancy that provides commercial due diligence services specifically for the healthcare and life sciences sector. If you would like to discuss how we can assist you, then please contact us.

Contact:

Katherine Mae

Business Development Manager

BiopharmaVantage, Oxford, UK

Email: [email protected]

Strategy Solutions | Commercial Due Diligence | Competitive Intelligence | Valuation | Licensing & Partnering

Website: http://www.biopharmavantage.com